Pharma have been retooling their therapeutic strategies and R&D priorities considerably over the past decade, shifting in and out of various disease areas. As they are the eventual home for many of the biotech programs we and other early stage VCs fund, its critical for us to understand Pharma’s needs and adjust our funding strategies in light of those strategic shifts.
